U.S. Food and Drug Administration Approves First CAR-T Lymphoma Therapy: Axicabtagene Ciloleucel
New York, NY (October 19, 2017) – The U.S. Food and Drug Administration (FDA) announced it has approved the use of axicabtagene ciloleucel (YescartaTM, Kite, a Gilead Company) to treat patients with large B-cell lymphoma who have relapsed or have…